Pharma industry insists European drugs are affordable

7 April 2022
europe_flag_eu_big

The European pharma industry has commissioned a  report on drug affordability which highlights its message that overall expenditure on therapies has remained stable.

Written by industry analyst IQVIA, the document includes estimates of total pharmaceutical spending for the past two decades, including hospital spending, taking into account discounts and rebates.

The researchers found that, in all of the 15 countries studied, spending on pharmaceuticals represents a fairly small proportion of overall spending, around 15%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical